Accelerated aging in breast cancer survivors is linked to treatments and tumor characteristics, with implications for ...
Taiho Pharmaceutical Co., Ltd.Araris Biotech AGTaiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris ...
Co., Ltd. announced a definitive agreement to acquire Araris Biotech AG, a Swiss biotech company specializing in next-generation antibody drug conjugates (ADCs). The $400 million deal, with additional ...
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad ...
Taiho Pharma to buy next-generation ADC drug discovery company ,Araris Biotech: Japan Tuesday, March 18, 2025, 16:00 Hrs [IST] Taiho Pharmaceutical Co., Ltd., an R&D-driven specia ...
Oncology Small Molecule Drugs Market Expected to Grow Significantly Due to Industry Advancements. Growing Demand for Personalized Medicine and Target ...
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today ...
Moleculin Biotech, Inc., (Moleculin or the Company), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has ...
Some workers have used various antimetabolites in an attempt to determine whether any of them block the synthesis of the floral stimulus, which could provide some indirect indications as to the ...
These drugs are subdivided into specific classes such as alkylating agents, antimetabolites, anthracyclines and topoisomerase inhibitors.
HOUSTON, March 11, 2025 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company") a late-stage pharmaceutical company with a broad portfolio of drug candidates ...
During the past 20 years, the advent of neoadjuvant, primary, and adjuvant concurrent chemoradiotherapy has improved cancer care dramatically. Significant contributions have been made by ...